Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study

Citadel J. Cabasag, Melina Arnold, Mark Rutherford, Jacques Ferlay, Aude Bardot, Eileen Morgan, John Butler, Dianne L. O'Connell, Gregg Nelson, Claus Høgdall, Tine Schnack, Anna Gavin, Mark Elwood, Louise Hanna, Charlie Gourley, Prithwish De, Nathalie Saint-Jacques, Lina Steinrud Mørch, Ryan R. Woods, Alon D. AltmanPeter Sykes, Paul A. Cohen, Orla McNally, Bjørn Møller, Paul Walsh, David S. Morrison, Freddie Bray, Isabelle Soerjomataram*


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


The aim of the study is to provide a comprehensive assessment of incidence and survival trends of epithelial ovarian cancer (EOC) by histological subtype across seven high income countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom). Data on invasive EOC diagnosed in women aged 15 to 99 years during 1995 to 2014 were obtained from 20 cancer registries. Age standardized incidence rates and average annual percentage change were calculated by subtype for all ages and age groups (15-64 and 65-99 years). Net survival (NS) was estimated by subtype, age group and 5-year period using Pohar-Perme estimator. Our findings showed marked increase in serous carcinoma incidence was observed between 1995 and 2014 among women aged 65 to 99 years with average annual increase ranging between 2.2% and 5.8%. We documented a marked decrease in the incidence of adenocarcinoma “not otherwise specified” with estimates ranging between 4.4% and 7.4% in women aged 15 to 64 years and between 2.0% and 3.7% among the older age group. Improved survival, combining all EOC subtypes, was observed for all ages combined over the 20-year study period in all countries with 5-year NS absolute percent change ranging between 5.0 in Canada and 12.6 in Denmark. Several factors such as changes in guidelines and advancement in diagnostic tools may potentially influence the observed shift in histological subtypes and temporal trends. Progress in clinical management and treatment over the past decades potentially plays a role in the observed improvements in EOC survival.

TidsskriftInternational Journal of Cancer
Udgave nummer9
Sider (fra-til)1763-1777
StatusUdgivet - 1. maj 2023

Bibliografisk note

Funding Information:
The authors would like to thank the ICBP management team of Cancer Research UK for managing the program, the ICBP SurvMark-2 Local Leads for advice to understand the data, for their contributions to the study protocol, and interpretation of the results, as well as the ICBP Clinical Committees for their advice. We are grateful to the ICBP SurvMark-2 Academic Reference Group for providing independent peer review and advice for the study protocol and analysis plan development. Finally, we thank the ICBP Program Board for their oversight and direction. A complete list of all investigators can be found in Table S7.

Funding Information:
ICBP is funded by the Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute NSW; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; NHS England; Norwegian Cancer Society; Public Health Agency Northern Ireland on behalf of the Northern Ireland Cancer Registry; DG Health and Social Care, Scottish Government; Western Australia Department of Health; Public Health Wales NHS Trust. All funders had no involvement in the study design, writing of the report, and the decision to submit the report for publication.

Publisher Copyright:
© 2022 International Agency for Research on Cancer. International Agency for Research on Cancer retains copyright and all other rights in the manuscript of this article as submitted for publication.


Dyk ned i forskningsemnerne om 'Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study'. Sammen danner de et unikt fingeraftryk.